P&G's drugs could go on the block

Procter & Gamble is cutting research and development of its pharmaceutical products and could sell some or all of its pharma brands, including the widely used osteoporosis med Actonel. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.